Q&A with Roberto Darienzo, Halo Pharmaceutical - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Roberto Darienzo, Halo Pharmaceutical
Roberto Darienzo, chief operating officer of Halo Pharmaceutical, describes strategic plans and industry trends.

Pharmaceutical Technology
Volume 37, Issue 6, pp. 68

Q&A with
Roberto Darienzo,
Chief Operating Officer, Halo Pharmaceutical



PharmTech:
What strategies are you planning to employ to remain competitive in the contract pharmaceutical development and commercial manufacturing industry?

Darienzo:
Clients expect us to be flexible, fast, and obviously to have competitive costs. We will achieve that by implementing best practices in operational excellence initiatives so that we have highly performing equipment, greatly trained and motivated teams, and that we are creative enough to find solutions to the most diverse problems our clients may face with their products. We believe we can generate ideas for development solutions, bringing those solutions to them better than our competition.

PharmTech:
Do you see a new industry trend emerging?

Darienzo:
There are several companies working not only in the discovery of new molecules, but also in taking known molecules or products and developing new ways of formulating them, new ways to release or deliver them to patients, reducing their abuse potential, improving their safety, efficacy, absorption, reducing side effects or effective dosage, etc. Obviously reducing the abuse potential of narcotic analgesic formulations (as well as other frequently abused drugs) is an active area at the moment, and an area in which Halo is currently working on numerous controlled substances.

PharmTech:
How is your company responding to regulators' intensifying emphasis on inspections and product quality?

Darienzo:
We are obliged to be absolutely perfect in our quality and compliance. So far, as a CDMO that started in 2008 that has had annual general and preapproval inspections because of our sterile area and the introduction of new products, we have yet to receive a 483 observation. This is very difficult, and never to be taken for granted, but it's a record we are determined to continue. Because of the number of clients we are now dealing with, we have an average of one audit per week, and have a tremendous source of GMP consulting advice. This gives us the opportunity to learn fast, to be fully updated on trends and new concepts, and to improve continuously every week.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here